Charles Ross Carter - 28 Jun 2024 Form 4 Insider Report for CERO THERAPEUTICS HOLDINGS, INC. (CERO)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CERO	Stock Option (Right to Buy)	Award	$0	+100,000		$0.000000	100,000	28 Jun 2024	Common Stock	100,000	$0.3000	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	All of the shares underlying this option will vest on the date of the acceptance of an Investigational New Drug application by the U.S. Food and Drug Administration, subject to the Reporting Person's continued service on such vesting date.